ATE402412T1 - Identifikation von verbindungen zur behandlung von nachstar - Google Patents

Identifikation von verbindungen zur behandlung von nachstar

Info

Publication number
ATE402412T1
ATE402412T1 AT05776264T AT05776264T ATE402412T1 AT E402412 T1 ATE402412 T1 AT E402412T1 AT 05776264 T AT05776264 T AT 05776264T AT 05776264 T AT05776264 T AT 05776264T AT E402412 T1 ATE402412 T1 AT E402412T1
Authority
AT
Austria
Prior art keywords
postcatar
identification
compounds
treatment
pco
Prior art date
Application number
AT05776264T
Other languages
English (en)
Inventor
Barbara Spruce
George Duncan
Alan Prescott
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee filed Critical Univ Dundee
Application granted granted Critical
Publication of ATE402412T1 publication Critical patent/ATE402412T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05776264T 2004-08-27 2005-08-26 Identifikation von verbindungen zur behandlung von nachstar ATE402412T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0419145.8A GB0419145D0 (en) 2004-08-27 2004-08-27 Treatment of posterior capsule opacification

Publications (1)

Publication Number Publication Date
ATE402412T1 true ATE402412T1 (de) 2008-08-15

Family

ID=33104737

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05776264T ATE402412T1 (de) 2004-08-27 2005-08-26 Identifikation von verbindungen zur behandlung von nachstar

Country Status (8)

Country Link
US (1) US20090036464A1 (de)
EP (1) EP1782065B1 (de)
AT (1) ATE402412T1 (de)
CA (1) CA2578117A1 (de)
DE (1) DE602005008445D1 (de)
ES (1) ES2310365T3 (de)
GB (1) GB0419145D0 (de)
WO (1) WO2006021811A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821093D0 (en) * 2008-11-18 2008-12-24 Modern Biosciences Plc Treatment
GB201003124D0 (en) * 2010-02-25 2010-04-14 Univ East Anglia Treatment of oxidative stress disorders
WO2011146863A1 (en) * 2010-05-21 2011-11-24 Alcon Research, Ltd. Surgical compositions containing sigma-receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966577A (en) * 1988-03-16 1990-10-30 Allergan, Inc. Prevention of lens-related tissue growth in the eye
GB0007842D0 (en) * 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
US7985405B2 (en) * 2002-09-17 2011-07-26 Jin Jun Zhang Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells
SE0202924D0 (sv) * 2002-10-03 2002-10-03 Pharmacia Groningen Bv Compositions for preventing posterior capsular opacification and the use therefor
GB0303640D0 (en) * 2003-02-17 2003-03-19 Univ Aberdeen An animal model

Also Published As

Publication number Publication date
US20090036464A1 (en) 2009-02-05
CA2578117A1 (en) 2006-03-02
GB0419145D0 (en) 2004-09-29
DE602005008445D1 (de) 2008-09-04
ES2310365T3 (es) 2009-01-01
EP1782065A2 (de) 2007-05-09
WO2006021811A3 (en) 2006-08-10
EP1782065B1 (de) 2008-07-23
WO2006021811A2 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
DE602005014955D1 (de) Verbindungen und verfahren zur behandlung von dyslipidämie
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DK1691892T3 (da) Anbrudsbestandig, coekstruderet doseringsform, der indeholder et aktivt middel og et modvirkende middel, og fremgangsmåde til fremstilling af samme
ATE457989T1 (de) Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
ATE537826T1 (de) Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
EP1595852A4 (de) Verfahren zur behandlung von ammoniakalischen stickstoffenthaltendem wasser
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
DE602004019897D1 (de) Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung vkrankungen eignen
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
ATE550015T1 (de) Verfahren und zusammensetzung zur behandlung von rhinitis
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
DE602004011494D1 (de) Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
ATE402412T1 (de) Identifikation von verbindungen zur behandlung von nachstar
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
EA200702136A1 (ru) Композиции станнсопорфина и их применение
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie
DE602004017425D1 (de) Pmcol zur behandlung von prostatakrebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1782065

Country of ref document: EP